Hertraz Injection (Trastuzumab): Advanced HER2+ Targeted Biological Therapy – Global Supply by Ernest Oncology
In the precision-driven oncology landscape of 2026, Hertraz Injection (containing the active ingredient Trastuzumab) stands as a critical biosimilar for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) overexpressing malignancies. Developed to match the clinical efficacy and safety of the reference biologic, Hertraz has expanded access to life-saving monoclonal antibody therapy for patients across the globe.
Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Hertraz to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, providing end-to-end cold-chain solutions and rigorous documentation for seamless medical procurement.
Technical Product Profile: Hertraz (Trastuzumab)
Hertraz is a recombinant DNA-derived humanized monoclonal antibody that selectively binds with high affinity to the extracellular domain of the HER2 protein.
Product Specifications
Active Ingredient: Trastuzumab (Biosimilar)
Available Strengths: 150 mg and 440 mg Multi-dose Vials
Pharmacological Class: HER2/neu Receptor Antagonist (Monoclonal Antibody)
Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics.
Primary Clinical Indications
HER2+ Metastatic Breast Cancer: Used as a first-line therapy in combination with taxanes or as a single agent in patients who have received previous chemotherapy.
Early Breast Cancer (EBC): Administered following surgery and chemotherapy to significantly reduce the risk of cancer recurrence.
Advanced Gastric Cancer: Indicated for HER2+ metastatic adenocarcinoma of the stomach or gastroesophageal junction in combination with cisplatin and a fluoropyrimidine.
Mechanism of Action: The Power of Targeted Blockade
Hertraz exerts its therapeutic effect by specifically targeting cells that overexpress the HER2 protein, which is responsible for aggressive tumor growth.
Receptor Inhibition: Hertraz binds to the HER2 receptors on the surface of cancer cells, blocking the chemical signals that tell the cells to grow and divide.
Immune System Recruitment: It marks the cancer cells for destruction by the body’s immune system through Antibody-Dependent Cellular Cytotoxicity (ADCC).
Prevention of HER2 Shedding: It prevents the cleavage of the HER2 receptor's extracellular domain, which can otherwise trigger potent oncogenic signaling.
Global Export Expertise: UK, USA, UAE, Australia, & South Africa
Ernest Oncology specializes in navigating the complex regulatory and logistical requirements for shipping sensitive biologicals from India to the world’s most demanding healthcare markets.
United Kingdom & London: We supply NHS Trusts and private oncology centers in London, adhering to all MHRA biological import protocols and batch release standards.
United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports at competitive price points.
Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure, temperature-monitored shipping to major healthcare hubs.
Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological import standards.
South Africa: Strengthening the African healthcare sector with affordable, high-quality cancer drugs from GMP facilities.
📞 Contact Ernest Oncology — Pharmaceutical Exporter from India
(Group of Ernest Pharmaceutical Pvt. Ltd.)
Partner with a verified leader for the bulk procurement of high-quality oncology biologics and targeted biosimilars.
🌐 Websites:
📧 Email:
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
🔗 Instant Chat:
